Malaria remains a major public health concern in many parts of the world, especially in sub-Saharan Africa, Southeast Asia, and Latin America. Resistance to older antimalarial medications has made combination therapies essential in effective treatment strategies. One of the most potent and WHO-endorsed Artemisinin-based Combination Therapies (ACTs) is Pyronaridine + Artesunate, known for its high efficacy against Plasmodium falciparum, including strains resistant to other antimalarials.

BluepillExpress is a globally trusted pharmaceutical manufacturing and export company specializing in high-quality antimalarial therapies. We provide third-party manufacturing services for Pyronaridine + Artesunate combinations tailored for governments, NGOs, healthcare institutions, and private label companies worldwide. Our WHO-GMP certified facilities ensure safety, efficacy, and international compliance.

Product Overview

Generic Name: Pyronaridine Tetraphosphate + Artesunate
Therapeutic Category: Antimalarial Combination Therapy
Pharmacological Class: Artemisinin-Based Combination Therapy (ACT)

Available Dosage Forms:

• Tablets (Film-coated, immediate-release)
• Pediatric dispersible tablets (on request)

Common Strengths Available:

• Pyronaridine Tetraphosphate 180 mg + Artesunate 60 mg (Adult Dose)
• Pyronaridine Tetraphosphate 60 mg + Artesunate 20 mg (Pediatric Dose)

Packaging Options:

• Blister packs (1×3, 1×6, 1×9 tablets)
• Strip packs for institutional supply
• Mono-cartons with multilingual inserts
• Child-resistant and anti-counterfeit packaging available

Pharmacopoeial Compliance: WHO PQ / IP / BP / USP (as per regulatory requirement)

Mechanism of Action

Pyronaridine:
A Mannich base antimalarial with potent schizonticidal activity against blood-stage Plasmodium falciparum. It interferes with hemozoin formation, leading to toxic accumulation of free heme within the parasite.

Artesunate:
A semi-synthetic derivative of artemisinin that generates free radicals when activated in the parasite’s food vacuole. This rapidly damages parasite proteins and membranes, leading to quick parasite clearance.

Synergistic Activity:
The combination of Pyronaridine and Artesunate offers complementary action:

• Artesunate acts quickly, reducing parasitemia within 24–48 hours
• Pyronaridine sustains the antimalarial effect, preventing recrudescence
  This synergy ensures high cure rates, reduced gametocyte carriage, and resistance suppression.

Indications

Pyronaridine + Artesunate is indicated for the treatment of:

• Acute uncomplicated malaria due to Plasmodium falciparum, including multi-drug resistant strains
• Co-infections involving P. vivax (when accompanied by appropriate follow-up therapy)
• Treatment of malaria in adults, adolescents, and children (based on body weight)
• Use in public health programs and government malaria control campaigns

Dosage and Administration

Adult Dosage (≥20 kg body weight):

• Pyronaridine 180 mg + Artesunate 60 mg: One tablet once daily for 3 consecutive days

Pediatric Dosage (5 kg to <20 kg):

• Based on weight bands; dispersible tablets available for children

Administration Guidelines:

• Should be taken with food to enhance absorption
• Strict adherence to 3-day regimen essential for full therapeutic benefit
• Not recommended for severe malaria (parenteral treatment preferred)
• Follow-up may be needed for P. vivax relapse prevention (with primaquine)

Pharmacokinetics

• Artesunate:
  • Rapid absorption; converted to active dihydroartemisinin (DHA)
  • Half-life: ~1 hour
  • Peak effect within 1–2 hours
• Pyronaridine:
  • Long half-life (~13–17 days), providing sustained activity
  • Slowly absorbed; peak levels in 2–4 hours
  • Lipophilic and highly protein-bound

This pharmacokinetic profile enables both rapid parasite clearance and long-term protection against recrudescence.

Advantages of Pyronaridine + Artesunate Combination

• High cure rate (>95%) even in drug-resistant malaria
• Short-course regimen: Only 3 days of once-daily dosing
• Improved adherence compared to older ACTs
• Favorable safety profile with minimal adverse effects
• WHO-endorsed combination for national malaria programs
• Low gametocyte carriage reduces transmission potential

Why Choose BluepillExpress for Manufacturing?

1. WHO-GMP Certified Production Units

We manufacture under strict GMP protocols, ensuring pharmaceutical excellence:

• Controlled-environment tablet manufacturing zones
• High-speed granulation, compression, and coating machinery
• Cleanroom packaging and microbial control compliance
• Separate production lines for antimalarial ACTs

2. Regulatory Documentation and Support

We provide complete regulatory support for product registration, including:

• Certificate of Pharmaceutical Product (COPP)
• Free Sale Certificate (FSC)
• WHO-type Certificate of Analysis (COA)
• Bioequivalence data (if required)
• Stability studies under ICH conditions
• CTD/ACTD dossiers for MOH approvals

3. Tailored Packaging and Private Labeling

We support:

• National malaria program packaging specifications
• QR codes, serialization, and anti-counterfeit measures
• Multilingual inserts (French, English, Arabic, Spanish)
• Customized artwork and branding for institutional or private markets

4. Global Export and Supply Chain Expertise

BluepillExpress supplies Pyronaridine + Artesunate to:

• Africa: Nigeria, DR Congo, Ethiopia, Ghana, Uganda
• Asia: Myanmar, Cambodia, India, Bangladesh
• Middle East: Iraq, Yemen, Sudan
• CIS and Latin America: Uzbekistan, Bolivia, Guatemala

Our efficient logistics partners ensure timely delivery for both bulk and branded shipments.

Quality Control and Assurance

All batches undergo rigorous in-house and third-party testing:

• Active Ingredient Assay (Pyronaridine and Artesunate)
• Dissolution Profile for consistent bioavailability
• Microbial Testing for contamination-free assurance
• Hardness, Friability, and Disintegration tests
• Stability Studies under climatic zones I–IV
• Packaging integrity and labeling accuracy checks

Our quality systems comply with IP, USP, BP, and WHO standards.

Third-Party Manufacturing Workflow at BluepillExpress

Step 1: Consultation and Product Finalization
Dosage, packaging, documentation, and market needs are discussed.

Step 2: Sample and Artwork Approval
Pilot batch and packaging samples developed and approved by client.

Step 3: Production and Quality Testing
Bulk production begins in GMP facilities, monitored with in-process QC checks.

Step 4: Packaging and Dispatch
Packed, labeled, and shipped with all necessary documentation.

Step 5: After-Sales Regulatory Support
Support provided for MOH queries, re-registration, and product variations.

Target Market and Clients

• Government Tenders and Public Health Institutions
• NGOs and Global Health Programs (e.g., The Global Fund, UNICEF, USAID)
• Private-label Antimalarial Brands
• Hospital Chains and Pharmacy Distributors
• Exporters and Aid Agencies Serving Malaria-Endemic Regions

Our Pyronaridine + Artesunate combination aligns with public health objectives and provides a cost-effective yet premium solution for malaria control.

Global Market Demand

• The global antimalarial drugs market is expected to cross USD 1 billion by 2028.
• ACTs like Pyronaridine + Artesunate are being adopted in more countries due to their superior cure rates.
• National Malaria Control Programs (NMCPs) increasingly prefer WHO-prequalified fixed-dose ACTs.
• BluepillExpress is strategically positioned to fulfill this demand through scalable, compliant, and affordable third-party manufacturing.

Conclusion

Pyronaridine + Artesunate offers a powerful, fast-acting, and safe antimalarial combination for the treatment of uncomplicated malaria. With increasing global demand for effective ACTs, having a reliable manufacturing partner is critical for success in institutional and commercial markets.

BluepillExpress is committed to supporting global health with quality-assured, affordable antimalarial solutions. Our third-party manufacturing model is built to deliver efficiency, compliance, and innovation — from sample development to final dispatch.